News & Events

Lumena swings for a $75M IPO to bear down on liver diseases

Fierce Biotech April 3, 2014 Damian Garde A month removed from raising $45 million in venture backing, San Diego’s Lumena Pharmaceuticals wants $75 million more as it plots a Wall Street debut, piling up cash to advance its two liver treatments.  Read More

read more

RiverVest Venture Partners Promotes Niall O’Donnell to Managing Director; Michael Berman Joins as Venture Partner

ST. LOUIS (April 2, 2014) – RiverVest Venture Partners today announced the promotion of Niall O’Donnell, Ph.D., to Managing Director. The life sciences venture capital firm also announced that medical device entrepreneur Mike Berman, a long-time member of RiverVest’s Scientific & Industry Advisory Board, has joined the firm as Venture Partner. O’Donnell focuses on biopharmaceutical, diagnostic and medical device investing. “Niall has been instrumental in the formation, development and clinical strategies of a number of our...

read more

“The Frank Drebin Approach to Healthcare”

“The Frank Drebin Approach to Healthcare” by RiverVest’s Niall O’Donnell, appearing in the Rady Business Journal, a Publication of the Rady School of Management. University of California, San Diego. Winter, 2014.  Read more

read more

ZS Pharma Announces Start of Enrollment of Phase 3 Extended Dosing Study of ZS-9 in Patients with Hyperkalemia

Coppell, Texas – March 25, 2014 – ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia. This randomized, double-blind, placebo-controlled study is designed to confirm, over a longer treatment period, the positive results previously reported for ZS003, a Phase 3 trial in which a once-daily dose of ZS-9 (5g or 10g)...

read more

Lumena Pharmaceuticals Raises $45 Million in Series B Financing

Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis SAN DIEGO – March 11, 2014 – Lumena Pharmaceuticals (Lumena), a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, today announced that it has secured $45 million in Series B financing. New Enterprise Associates (NEA) led the financing, with Adage Capital Management and RA Capital Management participating...

read more

RiverVest is investor in ZS Pharma’s $55 million financing

St. Louis Business Journal March 7, 2014 Brian Feldt, Reporter Two venture firms with St. Louis ties have invested in a Fort Worth-Texas-based pharmaceutical company’s $55 million financing round. ZS Pharma, which is developing treatments for kidney, cardiovascular, and liver disorders, closed on a $55 million Series D financing round on Wednesday. RiverVest Venture Partners, the Clayton-based venture capital firm, and the 3X5 Special Opportunity Fund, a RiverVest affiliate fund operating out of St. Louis and Portland that deals with...

read more

Companies To Watch: Otonomy Develops Proprietary Formulation For Ménière’s Disease

Pharmaceutical Online March 3, 2014 By Wayne Koberstein, executive editor Not to build a platform, but to create new, FDA -approved therapeutics for unserved indications in the ear, this developer focuses on novel delivery. SNAPSHOT Otonomy is a private company developing a line of new therapeutics for the ear using its own proprietary formulation of existing antibiotics and steroids. Its OTO-201 (reformulated ciprofloxacin) is now in Phase 3 trials for use during ear-tube placement surgery, and OTO-104 (reformulated dexamethasone) has...

read more

ZS Pharma Completes $55 Million Financing to Advance Its Novel Investigational Treatment for Hyperkalemia

Coppell, Texas – March 5, 2014 – ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, today announced that it has completed a $55 million Series D financing. The investor syndicate was led by Novo A/S and included new investors RA Capital, Adage Capital, Sofinnova Ventures, and one other top-tier institutional investor. The financing also included existing investors Alta Partners, Devon Park Bioventures, 3×5 Special Opportunity Fund, Salem Partners and...

read more

Tryton Medical Receives CE-mark for the Left Main Indication

Tryton Medical first & only coronary bifurcation stent indicated for Left Main  Durham, N.C. – February 13, 2014 – Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced that it has received CE Mark for the treatment of Left Main Coronary artery disease. With this approval, Tryton Medical becomes the first company to earn a CE Mark for this indication. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional...

read more

ZS Pharma Announces Positive Results from the Extended Treatment Phase of its Phase 3 Trial of ZS-9 in Patients with Hyperkalemia

Coppell, Texas –January 13, 2014 – ZS Pharma, a specialty pharmaceutical developing novel treatments for kidney, cardiovascular and liver disorders, today announced top-line results from the Extended Treatment Phase of ZS003, its pivotal Phase 3 trial of ZS-9. ZS-9 is a novel, investigational treatment for hyperkalemia. Top-line analyses of the safety and efficacy results showed that the trial met the pre-specified endpoint for the 12-day Extended Treatment Phase, demonstrating that both 5g and 10g of ZS-9 given once-daily maintained a...

read more
get more twitter followers free websites http://tw-rush.com/ for my examine